The pharmacogenetics of antidepressant treatments for depressive disorders

Min-Soo Lee

    Research output: Contribution to journalReview articlepeer-review

    6 Citations (Scopus)


    Pharmacological treatments for depressive disorder vary between individuals, with 30-40% of patients not responding sufficiently to antidepressant drugs. Different genetic makeups are thought to play an important role in the actions of antidepressants, but there are presently no gold-standard genetic markers for determining the response to antidepressants. In this report, we review the work focused on the association between antidepressant responses and genetic polymorphisms, including in the serotonin transporter, tryptophan hydroxylase, serotonin receptor 2A, serotonin receptor 6, G-protein β subunit, and the norepinephrine transporter.

    Original languageEnglish
    Pages (from-to)170-178
    Number of pages9
    JournalDrug Development Research
    Issue number3
    Publication statusPublished - 2005 Jul 1


    • Depression
    • Norepinephrine transporter
    • Pharmacogenetics
    • Serotonin transporter
    • Tryptophan hydroxylase

    ASJC Scopus subject areas

    • Drug Discovery
    • Organic Chemistry
    • Pharmacology


    Dive into the research topics of 'The pharmacogenetics of antidepressant treatments for depressive disorders'. Together they form a unique fingerprint.

    Cite this